Skip to content

Fix reorder columns #111

Fix reorder columns

Fix reorder columns #111

GitHub Actions / Unit Tests Summary failed Jul 23, 2024 in 0s

3 fail, 88 skipped, 250 pass in 1m 0s

341 tests  ±0   250 ✅ ±0   1m 0s ⏱️ -1s
136 suites ±0    88 💤 ±0 
  1 files   ±0     3 ❌ ±0 

Results for commit a3a38ca. ± Comparison against earlier commit dfd86b9.

Annotations

Check warning on line 0 in tables_ADA_adat04a

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_ADA_adat04a.qmd_result_v1_development (tables_ADA_adat04a) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-ADA-adat04a.R:1:1')
Snapshot of code has changed (variant 'development'):
old[4:27] vs new[4:27]
    Baseline Prevalence and Incidence of Treatment Emergent NAbs
    Protocol: A: Drug X Antibody
    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-                                                       A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
+                                                        A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
-                                                        (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
+                                                         (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-   Baseline Prevalence of NAbs                                                                                         
+   Baseline Prevalence of NAbs                                                                                          
-     Baseline evaluable patients for ADA                  134           132             0           0           266    
+     Baseline evaluable patients for ADA                   134           132             0           0           266    
-     Patients with a positive ADA sample at baseline      63             64             0           0           127    
+     Patients with a positive ADA sample at baseline       63             64             0           0           127    
-   Patients with a positive NAb sample at baseline         0             0              0           0            0     
+     Patients with a positive NAb sample at baseline        0             0              0           0            0     
-   Patient with no positive NAb samples at baseline        0             0              0           0            0     
+     Patient with no positive NAb samples at baseline       0             0              0           0            0     
-   Incidence of Treatment Emergent NAbs                                                                                
+   Incidence of Treatment Emergent NAbs                                                                                 
-     Post-baseline evaluable patients for ADA             134           132             0           0           266    
+     Post-baseline evaluable patients for ADA              134           132             0           0           266    
-     Patients positive for ADA                            66             59             0           0           125    
+     Patients positive for ADA                             66             59             0           0           125    
-   Patients positive for Treatment Emergent NAb            0             0              0           0            0     
+     Patients positive for Treatment Emergent NAb           0             0              0           0            0     
-   Treatment-induced NAb                                   0             0              0           0            0     
+     Treatment-induced NAb                                  0             0              0           0            0     
-   Treatment-enhanced NAb                                  0             0              0           0            0     
+     Treatment-enhanced NAb                                 0             0              0           0            0     
-   Patients negative for NAb                               0             0              0           0            0     
+     Patients negative for NAb                              0             0              0           0            0     
-   Treatment unaffected                                    0             0              0           0            0     
+     Treatment unaffected                                   0             0              0           0            0     
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
    
    NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s)
      Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s)

* Run `testthat::snapshot_accept('development/tables-ADA-adat04a')` to accept the change.
* Run `testthat::snapshot_review('development/tables-ADA-adat04a')` to interactively review the change.

Check warning on line 0 in tables_ADA_adat04b

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_ADA_adat04b.qmd_result_v1_development (tables_ADA_adat04b) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-ADA-adat04b.R:1:1')
Snapshot of code has changed (variant 'development'):
old[4:24] vs new[4:24]
    Baseline Prevalence and Incidence of Neutralizing Antibodies (NAbs)
    Protocol: A: Drug X Antibody
    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-                                                       A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
+                                                        A: Drug X   C: Combination   <Missing>   B: Placebo   All Drug X
-                                                        (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
+                                                         (N=134)       (N=132)         (N=0)      (N=134)      (N=266)  
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
-   Baseline Prevalence of NAbs                                                                                         
+   Baseline Prevalence of NAbs                                                                                          
-     Baseline evaluable patients for ADA                  134           132             0           0           266    
+     Baseline evaluable patients for ADA                   134           132             0           0           266    
-     Patients with a positive ADA sample at baseline      63             64             0           0           127    
+     Patients with a positive ADA sample at baseline       63             64             0           0           127    
-   Patients with a positive NAb sample at baseline         0             0              0           0            0     
+     Patients with a positive NAb sample at baseline        0             0              0           0            0     
-   Patients with no positive NAb sample at baseline        0             0              0           0            0     
+     Patients with no positive NAb sample at baseline       0             0              0           0            0     
-   Incidence of NAbs                                                                                                   
+   Incidence of NAbs                                                                                                    
-     Post-baseline evaluable patients for ADA             134           132             0           0           266    
+     Post-baseline evaluable patients for ADA              134           132             0           0           266    
-     Patients positive for ADA                            66             59             0           0           125    
+     Patients positive for ADA                             66             59             0           0           125    
-   Patients positive for NAb                               0             0              0           0            0     
+     Patients positive for NAb                              0             0              0           0            0     
-   Patients negative for NAb                              134           132             0           0           266    
+     Patients negative for NAb                             134           132             0           0           266    
-   ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
+   —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
    
    NAb = Neutralizing Antibodies ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies) Baseline evaluable patient for ADA = a patient with an ADA assay result from a baseline sample(s) Baseline evaluable patient for NAb = a patient with a NAb assay result from a baseline sample(s) Post-baseline evaluable patient for ADA = a patient with an ADA assay result from at least one post-baseline sample Post-baseline evaluable patient for NAb = a patient with a NAb assay result from at least one post-baseline sample Number of patients positive for ADA = the number of post-baseline evaluable patients for ADA determined to have Treatment Emergent ADA during the study period.
    Number of patients positive for NAb = the number (and percentage) of post-baseline evaluable patients for ADA determined to have at least one positive post-baseline NAb result during the study period. Number of patients negative for NAb = number of post-baseline evaluable patients with all negative post-baseline NAb results.

* Run `testthat::snapshot_accept('development/tables-ADA-adat04b')` to accept the change.
* Run `testthat::snapshot_review('development/tables-ADA-adat04b')` to interactively review the change.

Check warning on line 0 in tables_efficacy_rbmit01

See this annotation in the file changed.

@github-actions github-actions / Unit Tests Summary

tables_efficacy_rbmit01.qmd_result_v1_development (tables_efficacy_rbmit01) failed

tlg.catalog.pkg.Rcheck/tests/testthat/junit-result.xml [took 0s]
Raw output
Snapshot of code has changed (variant 'development'): ('test-tables-efficacy-rbmit01.R:1:1')
Snapshot of code has changed (variant 'development'):
old[11:33] vs new[11:33]
        Relative Reduction (%)                                     5.7%      
        p-value (RBMI)                                            0.8932     
    5                                                                        
-     Adjusted Mean (SE)                   -4.255 (0.653)     -2.857 (0.634) 
+     Adjusted Mean (SE)                   -4.263 (0.660)     -2.863 (0.634) 
-       95% CI                            (-5.546, -2.965)   (-4.109, -1.605)
+       95% CI                            (-5.567, -2.958)   (-4.114, -1.611)
-     Difference in Adjusted Means (SE)                       1.398 (0.915)  
+     Difference in Adjusted Means (SE)                       1.400 (0.925)  
-       95% CI                                               (-0.409, 3.205) 
+       95% CI                                               (-0.428, 3.228) 
-       Relative Reduction (%)                                    -32.9%     
+       Relative Reduction (%)                                    -32.8%     
-       p-value (RBMI)                                            0.1285     
+       p-value (RBMI)                                            0.1324     
    6                                                                        
-     Adjusted Mean (SE)                   -6.413 (0.712)     -4.166 (0.692) 
+     Adjusted Mean (SE)                   -6.429 (0.711)     -4.163 (0.687) 
-       95% CI                            (-7.821, -5.005)   (-5.533, -2.800)
+       95% CI                            (-7.834, -5.023)   (-5.520, -2.806)
-     Difference in Adjusted Means (SE)                       2.246 (1.005)  
+     Difference in Adjusted Means (SE)                       2.265 (0.987)  
-       95% CI                                                (0.260, 4.232) 
+       95% CI                                                (0.315, 4.216) 
-       Relative Reduction (%)                                    -35.0%     
+       Relative Reduction (%)                                    -35.2%     
-       p-value (RBMI)                                            0.0269     
+       p-value (RBMI)                                            0.0231     
    7                                                                        
-     Adjusted Mean (SE)                   -7.652 (0.775)     -4.939 (0.771) 
+     Adjusted Mean (SE)                   -7.677 (0.784)     -4.864 (0.764) 
-       95% CI                            (-9.185, -6.120)   (-6.465, -3.414)
+       95% CI                            (-9.228, -6.126)   (-6.375, -3.353)
-     Difference in Adjusted Means (SE)                       2.713 (1.099)  
+     Difference in Adjusted Means (SE)                       2.813 (1.111)  
-       95% CI                                                (0.538, 4.888) 
+       95% CI                                                (0.615, 5.011) 
-       Relative Reduction (%)                                    -35.5%     
+       Relative Reduction (%)                                    -36.6%     
-       p-value (RBMI)                                            0.0149     
+       p-value (RBMI)                                            0.0125     

* Run `testthat::snapshot_accept('development/tables-efficacy-rbmit01')` to accept the change.
* Run `testthat::snapshot_review('development/tables-efficacy-rbmit01')` to interactively review the change.